S Ugurel

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi request reprint Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogene
    K Schledzewski
    Department of Dermatology, Venerology, and Allergy, University Medical Centre Mannheim, Ruprecht Karls University Heidelberg, Germany
    J Pathol 209:67-77. 2006
  2. ncbi request reprint [Serum markers for melanoma]
    S Ugurel
    Klinische Kooperationseinheit Dermato Onkologie, Deutsches Krebsforschungszentrum Heidelberg Universitätshautklinik Mannheim
    Hautarzt 56:173-84; 185-6. 2005
  3. ncbi request reprint Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
    S Ugurel
    Department of Dermatology, Saarland University Hospital, Homburg/Saar, Germany
    J Clin Oncol 19:577-83. 2001
  4. ncbi request reprint Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study
    D Schadendorf
    Skin Cancer Unit, German Cancer Research Center and University Hospital Mannheim, Department of Dermatology, Mannheim, Germany
    Ann Oncol 17:1592-7. 2006
  5. ncbi request reprint Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients
    S Ugurel
    Department of Dermatology, The Saarland University Hospital, 66421 Homburg/Saar, Germany
    Clin Cancer Res 7:1282-6. 2001
  6. ncbi request reprint Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma
    W Fink
    Skin Cancer Unit German Cancer Research Center at the Department of Dermatology, University Hospital Mannheim, Germany
    Onkologie 27:540-4. 2004
  7. pmc Lack of clinical efficacy of imatinib in metastatic melanoma
    S Ugurel
    German Cancer Research Center Heidelberg, Department of Dermatology, University Hospital of Mannheim, Theodor Kutzer Ufer 1, D 68167 Mannheim, Germany
    Br J Cancer 92:1398-405. 2005
  8. ncbi request reprint Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
    D Schadendorf
    Skin Cancer Unit, German Cancer Research Center and University Hospital Mannheim, Mannheim
    Ann Oncol 17:563-70. 2006
  9. ncbi request reprint Multiple granular cell tumors and growth hormone deficiency in a child
    S Seiter
    Department of Dermatology, The Saarland University Hospital, Homburg/Saar, Germany
    Pediatr Dermatol 16:308-10. 1999
  10. ncbi request reprint Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod
    J Utikal
    Br J Dermatol 155:488-91. 2006

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogene
    K Schledzewski
    Department of Dermatology, Venerology, and Allergy, University Medical Centre Mannheim, Ruprecht Karls University Heidelberg, Germany
    J Pathol 209:67-77. 2006
    ..This improved approach will help to clarify the prognostic significance of lymphangiogenesis in malignant tumours...
  2. ncbi request reprint [Serum markers for melanoma]
    S Ugurel
    Klinische Kooperationseinheit Dermato Onkologie, Deutsches Krebsforschungszentrum Heidelberg Universitätshautklinik Mannheim
    Hautarzt 56:173-84; 185-6. 2005
    ..Serum markers are also not suitable for screening or for the diagnosis of primary melanomas...
  3. ncbi request reprint Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
    S Ugurel
    Department of Dermatology, Saarland University Hospital, Homburg/Saar, Germany
    J Clin Oncol 19:577-83. 2001
    ..CONCLUSION: Our data suggest that the angiogenic serum factors VEGF, bFGF, and IL-8 are useful predictive markers for overall and progression-free survival in melanoma patients...
  4. ncbi request reprint Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study
    D Schadendorf
    Skin Cancer Unit, German Cancer Research Center and University Hospital Mannheim, Department of Dermatology, Mannheim, Germany
    Ann Oncol 17:1592-7. 2006
    ..The purpose of this study was to test a dose-intensified regimen of temozolomide in melanoma patients with brain metastases in a prospective, open-label, multicentre phase II trial...
  5. ncbi request reprint Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients
    S Ugurel
    Department of Dermatology, The Saarland University Hospital, 66421 Homburg/Saar, Germany
    Clin Cancer Res 7:1282-6. 2001
    ..078), survival. Our results show a prognostic relevance of serum sFas/CD95 in melanoma patients, indicating that the evaluation of sFas/CD95 serum level may be important for the selection of therapeutic strategies...
  6. ncbi request reprint Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma
    W Fink
    Skin Cancer Unit German Cancer Research Center at the Department of Dermatology, University Hospital Mannheim, Germany
    Onkologie 27:540-4. 2004
    ..Response rates in first-line regimens range around 15-20%. Non-responders have a median survival around 6 months. Currently, no second-line treatment in advanced melanoma has been established...
  7. pmc Lack of clinical efficacy of imatinib in metastatic melanoma
    S Ugurel
    German Cancer Research Center Heidelberg, Department of Dermatology, University Hospital of Mannheim, Theodor Kutzer Ufer 1, D 68167 Mannheim, Germany
    Br J Cancer 92:1398-405. 2005
    ..In conclusion, this study did not reveal an efficacy of imatinib in advanced metastatic melanoma, regardless of the expression pattern of the imatinib target molecules c-kit and PDGF-R...
  8. ncbi request reprint Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
    D Schadendorf
    Skin Cancer Unit, German Cancer Research Center and University Hospital Mannheim, Mannheim
    Ann Oncol 17:563-70. 2006
    ..This randomized phase III trial was designed to demonstrate the superiority of autologous peptide-loaded dendritic cell (DC) vaccination over standard dacarbazine (DTIC) chemotherapy in stage IV melanoma patients...
  9. ncbi request reprint Multiple granular cell tumors and growth hormone deficiency in a child
    S Seiter
    Department of Dermatology, The Saarland University Hospital, Homburg/Saar, Germany
    Pediatr Dermatol 16:308-10. 1999
    ..The occurrence of multiple granular cell tumors in association with other clinical manifestations in childhood is discussed...
  10. ncbi request reprint Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod
    J Utikal
    Br J Dermatol 155:488-91. 2006
  11. ncbi request reprint [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma]
    C Pföhler
    Hautklinik und Poliklinik, Universitatskliniken des Saarlandes, Homburg Saar
    Hautarzt 55:171-5. 2004
    ..No systemic side effects were observed...
  12. ncbi request reprint Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma
    C Pföhler
    Department of Dermatology, The Saarland University Hospital, 66421 Homburg Saar, Germany
    Br J Dermatol 149:74-8. 2003
    ....
  13. ncbi request reprint Mucosal metastases in malignant melanoma
    W Fink
    Klinische Kooperationseinheit Dermatoonkologie des DKFZ an der Klinik für Dermatologie, Venerologie und Allergologie am Universitätsklinikum Mannheim, Germany
    Onkologie 26:249-51. 2003
    ....
  14. ncbi request reprint Systemic treatment in advanced melanoma: innovative perspectives
    S Ugurel
    Klinische Kooperationseinheit Dermato Onkologie, Deutsches Krebsforschungszentrum Heidelberg Universitäts Hautklinik Mannheim, Germany
    Onkologie 26:234-8. 2003
    ....
  15. ncbi request reprint Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread
    S Ugurel
    Br J Dermatol 147:621-4. 2002
  16. ncbi request reprint HLA-G in melanoma: A new strategy to escape from immunosurveillance?
    S Ugurel
    Department of Dermatology, The Saarland University Hospital, Homburg Saar, Germany
    Onkologie 25:129-34. 2002
    ....
  17. ncbi request reprint Detection of tumor-associated circulating mRNA in patients with disseminated malignant melanoma
    G Rappl
    Department of Dermatology, The Saarland University Hospital, Homburg/Saar, Germany
    Ann N Y Acad Sci 945:189-91. 2001
    ..Our group has recently assessed the potential value of extracellular RNA detection by RT-PCR in the peripheral blood of patients with metastatic melanoma...
  18. ncbi request reprint Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy
    S Ugurel
    Department of Dermatology, The Saarland University Hospital, Homburg/Saar, Germany
    Cancer 92:369-76. 2001
    ..CONCLUSIONS: This study shows increased sHLA-G serum concentrations in melanoma patients and additional enhancement upon treatment with IFN-alpha. The level of serum sHLA-G, however, had no negative impact on patients' prognosis...
  19. ncbi request reprint Identification of TIA-1+ and granzyme B+ cytotoxic T cells in lichen sclerosus et atrophicus
    T Gross
    Department of Dermatology, The Saarland University Hospital, Homburg/Saar, Germany
    Dermatology 202:198-202. 2001
    ..Our data also indicate that a cell-mediated immune response may play an important role in the pathogenesis of the disease...
  20. pmc Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
    A Hauschild
    Department of Dermatology, Christian Albrechts University, Kiel
    Br J Cancer 84:1036-42. 2001
    ..Further phase III trials with continuous infusion and higher dosages must be performed before any final conclusions can be drawn on the potential usefulness of IL-2 in biochemotherapy of advanced melanoma...
  21. doi request reprint Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
    K Spieth
    Department of Dermatology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Ann Oncol 19:801-6. 2008
    ....